Abstract
Background: JFMC37-0801 study was planned to offer superiority of 48 weeks treatment of capecitabine adjuvant chemotherapy to 24 weeks conventional treatment with respect to the primary endpoint of disease free survival (DFS) in patients with stage III colon and rectosigmoid cancer. Here, we report the final results of this study.